CNSP Stock Summary and Trading Ideas (CNS Pharmaceuticals | NASDAQ:CNSP)

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

CNS Pharmaceuticals trades on the NASDAQ stock market under the symbol CNSP.

As of April 6, 2026, CNSP stock price climbed to $2.32 with 19,175 million shares trading.

CNSP has a beta of 2.47, meaning it tends to be more sensitive to market movements. CNSP has a correlation of 0.19 to the broad based SPY ETF.

CNSP has a market cap of $1.44 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, CNSP traded as high as $132,000.00 and as low as $2.06.

CNSP has underperformed the market in the last year with a return of -84.5%, while the SPY ETF gained +18.0%. In the last 3 month period, CNSP fell short of the market, returning -56.2%, while SPY returned -3.3%. However, in the most recent 2 weeks CNSP has outperformed the stock market by returning +6.9%, while SPY returned +0.4%.

CNSP support price is $2.05 and resistance is $2.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNSP shares will trade within this expected range on the day.